News & Updates
Showing Multidisciplinary articles
Showing

Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
In the treatment of ischemic symptoms associated with peripheral arterial disease, the use of once-daily SID142 appears to be as good as twice-daily Renexin while having a favourable safety profile, as shown in a phase III study.

New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis
PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.

Circulating antioxidants play no protective role in breast, ovarian cancers
Genetically predicted circulating antioxidants do not appear to have a protective effect on the risk of breast cancer, ovarian cancer, or their histotypes, according to the results of a two-sample Mendelian randomization study.

Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.




